DigniCap® System Chosen for Cancer Patients at BMI Three Shires Hospital

Clinically-Proven Therapy Prevents Chemo-Related Hair Loss with Greater Comfort
and Precision

~ Northampton Residents Now Have Access to New State-of-the-Art Cancer Care
Therapy ~
LONDON (August 21, 2013)—The DigniCap® System, considered to be the most
scientifically-advanced scalp-cooling treatment available for reducing
chemotherapy-related hair loss in men and women today, has been chosen by BMI
Three Shires Hospital in Northampton as the preferred hair-loss treatment option
for use in its oncology practice. Available now for patients in Northampton and
surrounding communities, DigniCap® is the only system to offer scalp-cooling
above freezing levels with patented, built-in temperature sensors and a
precision cooling mechanism that allows for gradual and highly tolerable scalp
temperature fluctuations.

The DigniCap® System, developed by Dignitana, a world leader in scalp-cooling
technology, is a safe, gentle and effective treatment for avoiding hair loss
related to chemotherapy. The system continuously monitors temperature to ensure
comfort and consistent application of the treatment. Caps are specifically
designed so that the ears remain uncovered for added comfort and normal hearing
during the process, and the user-friendly system features an intuitive, touch
-screen control panel.

BMI Three Shires Hospital, situated within the site of St Andrew’s Hospital in
Northampton, is part of BMI Healthcare, Britain's leading provider of
independent healthcare with a nationwide network of hospitals and clinics,
performing more complex surgery than any other private healthcare provider in
the country. Oncologists at BMI Three Shires chose to offer the DigniCap® System
based on its superior tolerability and efficacy, noting that DigniCap is the
first scalp-cooling system that can be offered with clinical evidence,
confidence and consistent results at temperatures above freezing, which makes
for a less stressful and much more comfortable patient experience.

Clinical results show that eight out of 10 women in Europe and Asia who used the
DigniCap® System during chemotherapy retained their hair. Additional trials at
leading medical centers around the world have proven the system to be a viable
alternative for both women and men of diverse ethnicities.

DigniCap has been clinically evaluated, with excellent results, over the past
three years at several leading NHS cancer hospitals in the UK, and was recently
chosen as the preferred hair-loss treatment option by Imperial College
Healthcare NHS Trust, Royal Free London NHS Foundation Trust and St. George's
Healthcare.

In the United States, Dignitana recently announced that it has received US Food
and Drug Administration (FDA) approval for its Investigational Device Exemption
(IDE) and is now initiating a multi-center pivotal trial at major US medical
centers. Clinical trials will be conducted at the University of California, San
Francisco (led by Principal Investigator Hope S. Rugo, MD), Wake Forest Baptist
Medical Center (led by Principal Investigator Susan Melin, MD) and Weill Cornell
Breast Center (led by Principal Investigator Anne Moore, MD). The trial is
expected to open in the next few months at other prestigious medical centers in
New York and California. Further clinical results from investigations of the
efficacy of scalp-cooling with the DigniCap® System in both the US and the UK
will be presented at medical conferences and in publications throughout 2013.

BMI Three Shires Hospital’s Executive Director, Dominic Bath, comments: “BMI
Three Shires is pleased to be able to add the DigniCap® System to our portfolio
of oncology treatments and services. The impressive clinical evidence
demonstrating its safety and value assure us that it will of great benefit to
our Northampton cancer patients.”

“BMI Three Shires Hospital is known for its clinical excellence, state-of-the
-art medical innovation and compassionate service and care,” said Martin Waleij,
CEO of Dignitana. “We are proud that they have chosen to offer the
DigniCap® System to their patients, and we are honored to add Three Shires to
the growing list of medical establishments around the world that consider the
DigniCap® System an essential part of their comprehensive approach to cancer
care.”

“This alliance is for an initial reference order and augments our established
partnerships with three of the five largest private healthcare providers in the
UK,” Waleij adds. “Our aim is to be a key supplier for the five largest private
groups and a major contributor of scalp cooling services to cancer patients
within the public National Health Service, with whom we are currently in
discussion.”

For more information about the DigniCap® System offered at BMI Three Shires
Hospital please email info@bmihealthcare.co.uk.

About BMI Three Shires Hospital

BMI Three Shires Hospital is situated within the site of St Andrew’s Hospital in
Northampton and is part of BMI Healthcare, Britain's largest provider of
independent healthcare services. The hospital’s facilities, combined with the
latest in technology and on-site support services, enable consultants to
undertake a wide range of procedures from routine investigations to complex
surgery. This specialist expertise is supported by caring and professional
medical staff, with dedicated nursing teams and a Resident Medical Officer on
duty 24 hours a day, providing care within a friendly and comfortable
environment. BMI Three Shires is recognized as a BUPA Approved Breast Care Unit
and a BUPA Approved Bowel Centre Unit.

For more information please visit: http://www.bmihealthcare.co.uk/

About Dignitana AB (publ)
Dignitana AB, a Swedish medical device company, listed on the OMX Nasdaq First
North Stockholm, focused on the patented DigniCap® System, a medical device for
preventing hair-loss in chemotherapy patients and for technologies within the
area of medical cooling.

For more information visit www.dignitana.com

###